Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Dr. Lal Path Labs has completed the acquisition of a 100% stake in Shahbazkers Diagnostic Centre Private Limited. This makes SDCPL a wholly-owned subsidiary, strategically expanding the company's diagnostic network.
May 01 2026 19:05:00
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Dr. Lal Path Labs has made available the audio recording of its earnings conference call for Q4 & FY26. Investors and analysts can access the recording on the company's website for review.
Apr 30 2026 19:04:00
Dr. Lal Path Labs Ltd.
DR. LAL PATH LABS board approved the re-appointment of Dr. Arvind Lal as Executive Chairman and Whole-Time Director for a period of five years. This re-appointment will be effective from April 1, 2027, and is subject to the approval of shareholders at the upcoming Annual General Meeting.
Apr 30 2026 18:04:00
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs board recommended a final dividend of Rs. 4 per equity share for the financial year ended March 31, 2026. The record date for this dividend is June 26, 2026.
Apr 30 2026 18:04:00
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs announced the incorporation of a new wholly-owned subsidiary, Dr. Lal PathLabs FZCO, in Dubai, UAE. This entity will focus on strategic investments in diagnostics and allied activities, including potential acquisitions and joint ventures, marking an international expansion.
Apr 30 2026 18:04:00
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dr. Lal Path Labs announced FY26 consolidated financial results. Revenue increased 12.2% YoY to Rs.2,763 Cr, and net profit grew 3.6% YoY to Rs.510 Cr. However, Q4 net profit declined by 15.1% YoY.
Apr 30 2026 16:04:00
Dr. Lal PathLabs Ltd - 539524 - Incorporation Of A Wholly Owned Subsidiary Company
Dr. Lal Path Labs' board approved Q4 FY26 financial results and recommended a final dividend of Rs. 4 per share. The board also approved the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited for up to Rs. 20 crore and the incorporation of a wholly-owned subsidiary in Dubai, UAE, for international expansion.
Apr 30 2026 15:04:00
Dr. Lal PathLabs Ltd - 539524 - Senior Management Personnel (SMP)
Dr. Lal Path Labs' board approved Q4 FY26 financial results and recommended a final dividend of Rs. 4 per share. The board also approved the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited for up to Rs. 20 crore and the incorporation of a wholly-owned subsidiary in Dubai, UAE, for international expansion.
Apr 30 2026 15:04:00
Dr. Lal PathLabs Ltd - 539524 - Re-Appointment Of M/S Ernst & Young LLP (EY) As Internal Auditors And M/S A.G. Agarwal & Associates As Cost Auditors
Dr. Lal Path Labs' board approved Q4 FY26 financial results and recommended a final dividend of Rs. 4 per share. The board also approved the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited for up to Rs. 20 crore and the incorporation of a wholly-owned subsidiary in Dubai, UAE, for international expansion.
Apr 30 2026 15:04:00
Dr. Lal PathLabs Ltd - 539524 - The Record Date For The Purpose Of Payment Of Final Dividend Shall Be June 26, 2026
Dr. Lal Path Labs has set June 26, 2026, as the record date for its final dividend. The board recommended ₹4 per equity share for FY26, subject to shareholder approval at the upcoming AGM.
Apr 30 2026 15:04:00
Read More